GOTHENBERG, Sweden – November 5, 2021: Bruker today announced that it is collaborating with AstraZeneca to bring new state-of-the-art technology to a major Swedish national research center for drug development. Building on the AstraZeneca strategy of innovation through global partnerships, a collaboration between the Swedish NMR Center at the University of Gothenburg and AstraZeneca now offers advanced dynamic nuclear polarization (DNP) – nuclear magnetic resonance (NMR) technology and workflows from Bruker with the goal to significantly decrease drug development times.
Dr. Staffan Schantz, Associate Principal Scientist at AstraZeneca R&D
Prof. Goeran Karlsson, director of the Swedish NMR Center at the University of Gothenburg
Dr. Anna Codina, the director of the pharmaceutical magnetic resonance business at Bruker BioSpin
Dr. Staffan Schantz concluded: “We are entering a new phase for AstraZeneca. Creating an arena for open collaboration equipped with Bruker’s state-of-the-art technology will accelerate scientific development on a significant scale. In the coming years, we are expecting to see rapid development of different applications, not just in life sciences, but also in the fields of materials and environmental sciences.”
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of disease in three therapy areas – Oncology, CVRM and Respiratory. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
The University of Gothenburg is the third oldest of the Swedish universities and, with 37,000 students and 6,000 staff members, it is one of the largest universities in the Nordic countries.
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com
Media Contact (AstraZeneca)
Dr. Staffan Schantz
Associate Principal Scientist at AstraZeneca R&D
Media Contact (Bruker)
Thorsten Thiel, Ph.D.
VP of Group Marketing
T: +49 (721) 5161-6500